Literature DB >> 19587149

Evaluation of the specificity of pneumococcal polysaccharide enzyme-linked immunosorbent assay and the effect of serum adsorption based on standard pneumococcal serogroup- or serotype-specific rabbit antisera.

Hans-Christian Slotved1, Christina Guttmann, Charlotte Demuth Pedersen, Jasper Neergaard Jacobsen, Karen Angeliki Krogfelt.   

Abstract

Worldwide, Streptococcus pneumoniae (pneumococcus) is a major cause of morbidity and mortality, especially in infants and elderly people. Pneumococcal capsular polysaccharides are well characterized, and more than 90 different serotypes have been identified. Serotype-specific antibodies against the capsular polysaccharide are produced during infection. Detection of antibodies against pneumococci by enzyme-linked immunosorbent assay (ELISA) is performed according to WHO guidelines, using antigens provided by ATCC. However, testing the ELISA for specificity is challenging due to the difficulty in obtaining human naïve serum with pneumococcal antibodies as well as human serum with antibodies against a single serotype. The application of well-defined serotype-specific sera produced in animals to evaluate the specificity of the ATCC antigens and the effect of adsorption with cell wall and 22F polysaccharides has not been performed before, to our knowledge. In this study, the specificity of ATCC antigens (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) was tested by using commercial serotype-, serogroup-, and pool-specific pneumococcal rabbit antisera.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19587149      PMCID: PMC2745005          DOI: 10.1128/CVI.00143-09

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  17 in total

Review 1.  Typing of Streptococcus pneumoniae: past, present, and future.

Authors:  J Henrichsen
Journal:  Am J Med       Date:  1999-07-26       Impact factor: 4.965

Review 2.  Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides.

Authors:  Catherine M Wernette; Carl E Frasch; Dace Madore; George Carlone; David Goldblatt; Brian Plikaytis; William Benjamin; Sally A Quataert; Steve Hildreth; Daniel J Sikkema; Helena Käyhty; Ingileif Jonsdottir; Moon H Nahm
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

3.  An easy method for detection of nasopharyngeal carriage of multiple Streptococcus pneumoniae serotypes.

Authors:  Margit S Kaltoft; Uffe B Skov Sørensen; Hans-Christian Slotved; Helle Bossen Konradsen
Journal:  J Microbiol Methods       Date:  2008-09-05       Impact factor: 2.363

4.  Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay.

Authors:  N F Concepcion; C E Frasch
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

5.  Pneumococcal capsular polysaccharide preparations may contain non-C-polysaccharide contaminants that are immunogenic.

Authors:  X Yu; Y Sun; C Frasch; N Concepcion; M H Nahm
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

6.  Are the enzyme immunoassays for antibodies to pneumococcal capsular polysaccharides serotype specific?

Authors:  A Soininen; G van den Dobbelsteen; L Oomen; H Käyhty
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

7.  Invasive pneumococcal infections in Denmark from 1995 to 1999: epidemiology, serotypes, and resistance.

Authors:  Helle Bossen Konradsen; Margit Staum Kaltoft
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

8.  Purification and structure characterization of the active component in the pneumococcal 22F polysaccharide capsule used for adsorption in pneumococcal enzyme-linked immunosorbent assays.

Authors:  Ian Chr Skovsted; Mette B Kerrn; Jacob Sonne-Hansen; Lis E Sauer; Annie Kleis Nielsen; Helle Bossen Konradsen; Bent O Petersen; Nils T Nyberg; Jens Ø Duus
Journal:  Vaccine       Date:  2007-07-05       Impact factor: 3.641

9.  Structure of the capsular polysaccharide of pneumococcal serotype 11A reveals a novel acetylglycerol that is the structural basis for 11A subtypes.

Authors:  Edward R Zartler; Richard J Porambo; Carrie L Anderson; Lorenzo H Chen; Jigui Yu; Moon H Nahm
Journal:  J Biol Chem       Date:  2008-12-29       Impact factor: 5.157

10.  Immune response to pneumococcal polysaccharides 4 and 14 in elderly and young adults. I. Antibody concentrations, avidity and functional activity.

Authors:  Kris Kolibab; S Louise Smithson; Anne K Shriner; Sadik Khuder; Sandra Romero-Steiner; George M Carlone; M A Julie Westerink
Journal:  Immun Ageing       Date:  2005-06-27       Impact factor: 6.400

View more
  4 in total

1.  Interlaboratory comparison of three multiplexed bead-based immunoassays for measuring serum antibodies to pneumococcal polysaccharides.

Authors:  Melissa J Whaley; Charles Rose; Joseph Martinez; Gouri Laher; Deborah L Sammons; Jerry P Smith; John E Snawder; Ray Borrow; Raymond E Biagini; Brian Plikaytis; George M Carlone; Sandra Romero-Steiner
Journal:  Clin Vaccine Immunol       Date:  2010-03-24

2.  Association between serotype-specific antibody response and serotype characteristics in patients with pneumococcal pneumonia, with special reference to degree of encapsulation and invasive potential.

Authors:  Simon Athlin; Margit Kaltoft; Hans-Christian Slotved; Björn Herrmann; Hans Holmberg; Helle Bossen Konradsen; Kristoffer Strålin
Journal:  Clin Vaccine Immunol       Date:  2014-09-17

3.  Clinical and Microbiological Factors Associated with High Nasopharyngeal Pneumococcal Density in Patients with Pneumococcal Pneumonia.

Authors:  Helena Alpkvist; Simon Athlin; Pontus Nauclér; Björn Herrmann; Guma Abdeldaim; Hans-Christian Slotved; Jonas Hedlund; Kristoffer Strålin
Journal:  PLoS One       Date:  2015-10-14       Impact factor: 3.240

4.  Serotypes With Low Invasive Potential Are Associated With an Impaired Antibody Response in Invasive Pneumococcal Disease.

Authors:  Nils Littorin; Fabian Uddén; Jonas Ahl; Fredrik Resman; Hans-Christian Slotved; Simon Athlin; Kristian Riesbeck
Journal:  Front Microbiol       Date:  2018-11-15       Impact factor: 5.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.